Pamiparib
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Pamiparib
Description :
Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor[1][2].Product Name Alternative :
BGB-290UNSPSC :
12352005Hazard Statement :
H315, H319, H320Target :
PARPType :
Reference compoundRelated Pathways :
Cell Cycle/DNA Damage; EpigeneticsApplications :
Cancer-programmed cell deathField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/Pamiparib.htmlPurity :
99.96Solubility :
DMSO : 50 mg/mL (ultrasonic)Smiles :
O=C1NN=C2CN(CCC3)[C@@]3(C)C(N4)=C2C5=C4C=C(F)C=C51Molecular Formula :
C16H15FN4OMolecular Weight :
298.32Precautions :
H315, H319, H320References & Citations :
[1]Changyou Zhou, et al. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors. WO 2013097225 A1.|[2]Friedlander M, et al. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. Lancet Oncol. 2019 Sep;20 (9) :1306-1315.|[3]Zhiyu Tang, et al. Abstract 1653: BGB-290: A highly potent and specific PARP1/2 inhibitor potentiates anti-tumor activity of chemotherapeutics in patient biopsy derived SCLC models. Cancer Research. August 2015, Volume 75, Issue 15.|[4]Shiv K. Gupta, et al. Abstract 3505: Inhibition of PARP activity by BGB-290 potentiates efficacy of NSC 362856 in patient derived xenografts of glioblastoma multiforme. Cancer Research. August 2015, Volume 75, Issue 15Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
LaunchedIsoform :
PARPCAS Number :
[1446261-44-4]

